BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37973025)

  • 41. Radiogenomics Provides Insights into Gliomas Demonstrating Single-Arm 1p or 19q Deletion.
    Lasocki A; Buckland ME; Molinaro T; Xie J; Gaillard F
    AJNR Am J Neuroradiol; 2023 Nov; 44(11):1270-1274. PubMed ID: 37884300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic and predictive biomarkers in central nervous system tumours: the molecular state of play.
    Satgunaseelan L; Sy J; Shivalingam B; Sim HW; Alexander KL; Buckland ME
    Pathology; 2024 Mar; 56(2):158-169. PubMed ID: 38233331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. ATRX immunohistochemistry can help refine 'not elsewhere classified' categorisation for grade II/III gliomas.
    Burford C; Laxton R; Sidhu Z; Aizpurua M; King A; Bodi I; Ashkan K; Al-Sarraj S
    Br J Neurosurg; 2019 Oct; 33(5):536-540. PubMed ID: 31018710
    [No Abstract]   [Full Text] [Related]  

  • 44. [Classification and Diagnosis of Adult-Type Diffuse Gliomas].
    Ohno M; Sugino H
    No Shinkei Geka; 2023 Sep; 51(5):760-770. PubMed ID: 37743327
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Update on quality assurance in neuropathology: Summary of the round robin trials on
    Pohl S; Dimitrova L; Grassow-Narlik M; Jöhrens K; Acker T; Dohmen H; Herms J; Dorostkar M; Hartmann C; Hasselblatt M; Neumann M; Reifenberger G; Felsberg J; Schüller U; Zoubaa S; Lorenz J; Rothhammer-Hampl T; Mauch-Mücke K; Riemenschneider MJ
    Clin Neuropathol; 2023; 42(3):112-121. PubMed ID: 36999511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Precision Medicine for IDH-mutant Diffuse Glioma(Lower-grade Glioma)].
    Mukasa A
    No Shinkei Geka; 2022 Jan; 50(1):8-18. PubMed ID: 35169082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.
    Garton ALA; Kinslow CJ; Rae AI; Mehta A; Pannullo SC; Magge RS; Ramakrishna R; McKhann GM; Sisti MB; Bruce JN; Canoll P; Cheng SK; Sonabend AM; Wang TJC
    J Neurosurg; 2020 May; 134(5):1357-1367. PubMed ID: 32384274
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microvascular characteristics of lower-grade diffuse gliomas: investigating vessel size imaging for differentiating grades and subtypes.
    Guo H; Kang H; Tong H; Du X; Liu H; Tan Y; Yang Y; Wang S; Zhang W
    Eur Radiol; 2019 Apr; 29(4):1893-1902. PubMed ID: 30276676
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular classification of gliomas.
    Masui K; Mischel PS; Reifenberger G
    Handb Clin Neurol; 2016; 134():97-120. PubMed ID: 26948350
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
    Brandner S; McAleenan A; Jones HE; Kernohan A; Robinson T; Schmidt L; Dawson S; Kelly C; Leal ES; Faulkner CL; Palmer A; Wragg C; Jefferies S; Vale L; Higgins JPT; Kurian KM
    Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12790. PubMed ID: 34958131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features.
    Deng MY; Sill M; Chiang J; Schittenhelm J; Ebinger M; Schuhmann MU; Monoranu CM; Milde T; Wittmann A; Hartmann C; Sommer C; Paulus W; Gärtner J; Brück W; Rüdiger T; Leipold A; Jaunmuktane Z; Brandner S; Giangaspero F; Nozza P; Mora J; Morales la Madrid A; Cruz Martinez O; Hansford JR; Pietsch T; Tietze A; Hernáiz-Driever P; Stoler I; Capper D; Korshunov A; Ellison DW; von Deimling A; Pfister SM; Sahm F; Jones DTW
    Acta Neuropathol; 2018 Aug; 136(2):239-253. PubMed ID: 29766299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
    Weller M; Stupp R; Hegi ME; van den Bent M; Tonn JC; Sanson M; Wick W; Reifenberger G
    Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv100-8. PubMed ID: 23095825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems.
    Sonoda Y
    Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular classification of adult gliomas: recent advances and future perspectives.
    Barritault M; Meyronet D; Ducray F
    Curr Opin Oncol; 2018 Nov; 30(6):375-382. PubMed ID: 30148717
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B
    Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H3K27me3 immunostaining is diagnostic and prognostic in diffuse gliomas with oligodendroglial or mixed oligoastrocytic morphology.
    Ammendola S; Caldonazzi N; Simbolo M; Piredda ML; Brunelli M; Poliani PL; Pinna G; Sala F; Ghimenton C; Scarpa A; Barresi V
    Virchows Arch; 2021 Nov; 479(5):987-996. PubMed ID: 34165590
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [How molecular biology can improve the clinical diagnosis of gliomas?].
    D'Haene N; Blanchard O; De Nève N; Evens J; Maris C; Rorive S; Le Mercier M; Salmon I
    Rev Med Brux; 2016; 37(3):152-158. PubMed ID: 28525188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.